Ulrich Brennscheidt

Title: Ulrich Brennscheidt: Innovator in Lung Cancer Treatment

Introduction

Ulrich Brennscheidt is a notable inventor based in Riehen, Switzerland. He has made significant contributions to the field of oncology, particularly in the treatment of lung cancer. His innovative approach focuses on determining the sensitivity of lung cancer cells to specific chemotherapy agents.

Latest Patents

Brennscheidt holds a patent for a method titled "Determination of responders to chemotherapy." This invention relates to assessing whether a biological sample containing human lung cancer cells is sensitive to a combination of an epidermal growth factor receptor inhibitor and a chemotherapeutic agent. The method involves determining the overexpression of a phosphorylated AKT protein and/or a phosphorylated MAPK protein in the biological sample. This groundbreaking work aims to enhance the selection of effective treatments for lung cancer patients.

Career Highlights

Ulrich Brennscheidt is associated with Hoffmann-La Roche Inc., a leading company in the pharmaceutical industry. His work at this esteemed organization has allowed him to contribute to advancements in cancer treatment and patient care. With a focus on innovative methodologies, Brennscheidt continues to push the boundaries of medical research.

Collaborations

Brennscheidt collaborates with several professionals in his field, including Otmar Herrgott, who serves as a Legal Representative, and Astrid Heller. These collaborations enhance the development and implementation of his innovative ideas.

Conclusion

Ulrich Brennscheidt's contributions to lung cancer treatment through his patented methods demonstrate his commitment to improving patient outcomes. His work at Hoffmann-La Roche Inc. and collaborations with other professionals highlight the importance of innovation in the medical field.